Novo Nordisk’s Q1 GLP-1 Sales Hit DKK13.9 B as Rival Lilly’s Mounjaro Surges
Novo Nordisk’s GLP-1 franchise generated DKK13.9 billion ($2.1 billion) in Q1 sales, a 150% year-over-year increase, while Eli Lilly’s Mounjaro posted $804 million, up 80% sequentially. Both companies announced plans to add new manufacturing capacity in Denmark and Indiana to meet surging demand.
1. Intensified GLP-1 Competition
The market for GLP-1 therapies has entered a pivotal phase as Novo Nordisk’s Ozempic and Wegovy compete directly with Eli Lilly’s Mounjaro in obesity and type 2 diabetes. Both firms are leveraging label expansions and marketing pushes to capture share in a rapidly growing segment.
2. Q1 Sales Comparison
In the first quarter, Novo Nordisk reported DKK13.9 billion ($2.1 billion) in GLP-1 revenues, up 150% year-over-year, while Eli Lilly’s Mounjaro achieved $804 million in sales, marking an 80% sequential gain. The widening sales gap has prompted renewed focus on pricing strategies and patient access programs.
3. Manufacturing Expansion Plans
To address potential supply bottlenecks, Novo Nordisk plans two new production facilities in Denmark, scheduled for completion in 2026, while Eli Lilly is building an mRNA-based fill-finish plant in Indiana. These expansions aim to boost output by over 50% by 2027 to meet global demand.